TITLE

The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: A preliminary trial

AUTHOR(S)
Chaput, Yves; Magnan, Annick; Gendron, Alain
PUB. DATE
January 2008
SOURCE
BMC Psychiatry;2008, Vol. 8, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Patients with major depression refractory to repeated pharmacological trials (TRD) may remain symptomatic for many years after their index episode. Augmentation strategies (with lithium or an atypical antipsychotic) or combining an antidepressant with short-term psychotherapy have been used with relative success in these patients. The aim of this study was to assess the effectiveness of the concomitant administration of quetiapine, an atypical antipsychotic, or placebo, to cognitive-behavior therapy (CBT) in TRD. Methods: Thirty-one patients who met entrance criteria for unipolar major depression (TRD stage II or greater) underwent 3 weeks of lithium augmentation after which non-responders (N = 22) were randomized to receive either quetiapine or placebo as an adjunct to their 12 weekly CBT sessions (quetiapine/CBT or placebo/CBT groups). Primary efficacy measures were the Hamilton and the Montgomery-Asberg rating scales for depression. Results: Overall, there was a significant reduction in both primary efficacy measure scores at LOCF for the 11 patients in the quetiapine/CBT group but not in the placebo/CBT treated patients. Patients in the quetiapine/CBT group, compared to those receiving placebo/CBT, showed a significantly greater degree of improvement on one primary and one secondary efficacy measure, were more likely to complete the trial and, completed a greater number of CBT sessions. Conclusion: Although preliminary, our results suggest that the adjunctive administration of quetiapine to CBT may prove useful in the treatment of stage II TRD. Trial Registration: Current Controlled Trials ISRCTN12638696.
ACCESSION #
35702832

 

Related Articles

  • Clinical Data sees positive results from pivotal depression drug trial.  // PharmaWatch: CNS;Oct2007, Vol. 6 Issue 10, p11 

    The article reports on the positive results from a Phase III study of its investigative compound Vilazodone for the treatment of depression by Clinical Data Inc. in the U.S. The primary and supportive secondary efficacy endpoints were met. The randomized, double-blind, placebo-controlled study...

  • The debate over placebo controls continues.  // Drug Utilization Review;Feb2002, Vol. 18 Issue 2, p10 

    Debates on the use of placebo-controlled trials in the United States (U.S.). Circumstances where placebo-controlled trial may be ethically acceptable; How the U.S. Food and Drug Administration accepted the use of placebo-controlled trials when a proven policy exists; Purpose of placebo controls.

  • Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. Moreno, Santiago G.; Sutton, Alex J.; Turner, Erick H.; Abrams, Keith R.; Cooper, Nicola J.; Palmer, Tom M.; Ades, A. E. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/29/2009, Vol. 339 Issue 7719, p494 

    Objective To assess the performance of novel contour enhanced funnel plots and a regression based adjustment method to detect and adjust for publication biases. Design Secondary analysis of a published systematic literature review. Data sources Placebo controlled trials of antidepressants...

  • ACAPODENE LOWERED CHOLESTEROL AND RAISED HDL IN PHASE III.  // Biotech Business;Aug2006, Vol. 19 Issue 8, p8 

    The article reports the results of the lipid interim analysis of the phase III clinical trial of Acapodene® by GTx Inc. The drug is being developed for the treatment of multiple serious side effects of androgen deprivation therapy in men with advance prostate cancer. The results revealed that...

  • Drugs on trial. Dunkin, Mary Anne // Arthritis Today;Sep/Oct92, Vol. 6 Issue 5, p28 

    Reports on the conduction of clinical trials to evaluate the effectivity of drugs for a certain disease. Phases of the clinical trial; Approval from the Food and Drug Administration; Approval of new uses of drugs for conditions besides the one for which the drug was first approved; Benefits and...

  • Comparative randomised trial of online cognitive-behavioural therapy and an information website for depression: 12-month outcomes. Mackinnon, Andrew; Griffiths, Kathleen M.; Christensen, Helen // British Journal of Psychiatry;Feb2008, Vol. 192 Issue 2, p130 

    Background: An earlier paper reported positive outcomes immediately following access to a cognitive-behavioural therapy (CBT) internet intervention and a depression information website.Aims: To determine 6-month and 12-month outcomes of the interventions relative to a...

  • Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology. Potter, William; Mallinckrodt, Craig; Detke, Michael // Pharmaceutical Medicine - New Zealand;Apr2014, Vol. 28 Issue 2, p53 

    Placebo response impacts the development of treatments for central nervous system disorders. Despite significant attention in scientific literature, the magnitude of placebo response continues to increase. The present work reviews empirical and theoretical literature on associations of trial...

  • Reducing Placebo Response: Triple Blinding & Setting Expectations. Kirby, Louis; Borwege, Steve; Christensen, James; Weber, Christopher; McCarthy, Craig // Applied Clinical Trials;Nov2005, Vol. 14 Issue 11, p48 

    The article discusses triple blinding and setting expectations for eliminating factors that influence the placebo response during the clinical trial process in pain, anxiety and depression. It outlines a variety of the site-subject interaction components which include subject psychological...

  • Disparate findings on a link between SSRIs and suicide. Paist, Scott S.; Russell, John J. // Patient Care;May2005, Vol. 39 Issue 5, p62 

    Presents information on two articles about the occurrences of suicide and intentional self-harm following the initiation of selective serotonin reuptake inhibitor (SSRI) therapy for depression. "Selective Serotonin Reuptake Inhibitors and Suicide in Adults: Meta-analysis of Drug Company Data...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics